Save on Elranatamab-BCMM with Coupons, Discounts & Savings Programs

Elranatamab-BCMM is available as a 76 mg/1.9 mL (40 mg/mL) or
44 mg/1.1 mL (40 mg/mL) in a single-dose vial.

Elranatamab-BCMM is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T‑cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Elranatamab-BCMM works by helping your immune system slow or stop the spread of cancer cells.

Elranatamab-BCMM is started low and they gradually increased up to 76 mg biweekly in week 25.

Elranatamab-BCMM is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Elranatamab-BCMM:

• Tiredness
• Injection site reaction, such as redness, itching, pain, bruising, rash, swelling, tenderness
• Diarrhea
• Muscle and bone pain
• Decreased appetite
• Rash
• Cough
• Nausea
• Fever

Serious side effects are rare with Elranatamab-BCMM. Tell your healthcare provider right away if you develop any signs or symptoms of an infection during treatment with Elranatamab-BCMM. Also let them know if you symptoms of liver problems such as tiredness, loss of appetite, pain in your right upper stomach-area (abdomen), dark urine, and yellowing of your skin or the white part of your eyes.

The following medications may interact with Elranatamab-BCMM:

• For certain CYP substrates, minimal changes in the concentration may lead to serious adverse reactions. Monitor for toxicity or drug concentrations of such CYP substrates when co-administered with Elranatamab-BCMM
• Elranatamab-BCMM causes release of cytokines that may suppress activity of cytochrome P450 (CYP) enzymes, resulting in increased exposure of CYP substrates. Increased exposure of CYP substrates is more likely to occur after the first dose of Elranatamab-BCMM Day 1 and up to 14 days after the 32 mg dose on Day 4 and during and after CRS

Various FDA-approved generic manufacturers

Elranatamab-BCMM may harm your unborn baby.

Females who are able to become pregnant:

• Your healthcare provider should do a pregnancy test before you start treatment with Elranatamab-BCMM
• You should use effective birth control (contraception) during treatment and for 4 months after your last dose of Elranatamab-BCMM
• Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with Elranatamab-BCMM

• Elrexfio